Are you ready for the unique opportunities and challenges coming to clinical trials in the next decade?
It’s a landmark time for clinical trials, with a whirlwind of recent changes that shows no signs of slowing down. From remote monitoring to virtual trials to lessons learned from COVID-19, those involved in conducting clinical trials must transform their operations.
Pamela Tenaerts, MD, MBA, executive director of the Clinical Trials Transformation Initiative (CTTI), a public-private partnership founded by Duke University and the FDA, and CTTI’s co-chair, John H. Alexander, MD, MHS, FACC, will discuss the future of clinical research — one that is patient-centered and easily accessible, integrated with health processes, leverages available data and improves public health — and the critical role of organizational partnerships to achieve quality results in the next generation of clinical trials.
- Multi-stakeholder perspectives on the future of clinical research
- Future goals for clinical trials by 2030 using a Quality by Design approach
- Potential impacts of the COVID-19 pandemic to positively transform clinical trials
- How organizational collaborative efforts can help advance and enhance the clinical trials landscape
- Actionable tools and resources available from CTTI that can help organizations and researchers prepare and adapt for future change
If you conduct clinical trials, this presentation is a must. Join us by registering today.
CTTI now comprises more than 80 organizations from across the clinical trial enterprise. Members include representatives of government agencies, industry representatives, patient advocacy groups, professional societies, investigator groups, academic institutions, and other interested parties. CTTI’s mission is to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials.